title: Comparison of intraocular pressure elevation after anterior versus posterior subtenon triamcinolone acetonide acetate injection: a retrospective study.
abstract: OBJECTIVE
  To compare the profiles of elevated intraocular pressure (IOP) after anterior and posterior subtenon injections (PSTIs) of triamcinolone.
  
  
  METHODS
  In this retrospective case series, 131 patients (131 eyes) with a single anterior subtenon injection (ASTI) of triamcinolone acetonide acetate (20 mg in 0.5 mL) and 49 patients (49 eyes) with a single PSTI of triamcinolone acetonide acetate (40 mg in 0.4 mL) were studied for changes in IOP. Changes in IOP compared with the baseline and fellow eyes were analyzed for both the ASTI and PSTI groups.
  
  
  RESULTS
  The study revealed that ASTI was 2.4 times more likely (95% confidence interval, 1.02-5.9) to have an IOP elevation >21 mmHg when compared with the PSTI (P = 0.0389). Twenty-one percent (28 of 131) of eyes having an IOP >21 mmHg were found in the ASTI group, while only 12% (6 of 49) were found in the PSTI group. Similarly, ASTI was 5.3 times more likely (95% confidence interval, 1.2-22.5) to have an IOP >30 mmHg compared with the PSTI (P = 0.03, one-tailed). Anterior subtenon injection had 7% (9 of 131) of eyes with IOP >30 mmHg, while only 2% (1 of 49) were present in the PSTI group. Age was negatively associated with IOP elevation (P < 0.05), and the baseline IOP was positively associated with IOP elevation (P < 0.05). The mean IOP elevation from the baseline was also found to be greater in ASTI (3.1 mmHg) than in PSTI (1.8 mmHg; P = 0.02, generalized estimating equation).
  
  
  CONCLUSIONS
  An ASTI of triamcinolone acetonide may bear a higher risk of developing elevated IOP than a PSTI of triamcinolone acetonide.
authors.affiliation: Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical College, Wenzhou, Zhejiang, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Liu
authors.forename: Yingzi
authors.initials: Y
authors.lastname: Li
authors.forename: Yin
authors.initials: Y
authors.lastname: Zhang
authors.forename: Wennan
authors.initials: W
authors.lastname: Du
authors.forename: Shumao
authors.initials: S
authors.lastname: Sun
authors.forename: Bing
authors.initials: B
authors.lastname: Lin
authors.forename: Hao
authors.initials: H
authors.lastname: Chen
authors.forename: Lingyun
authors.initials: L
authors.lastname: Cheng
mesh_terms: D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D056965:Injections, Intraocular / Q000009:adverse effects; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced*; D012189:Retrospective Studies; D012307:Risk Factors; D058475:Tenon Capsule / Q000187:drug effects*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects*; D014792:Visual Acuity
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide